Not connected to GLP3Planner: GLP3Planner has no connection to “GLP3-B” capsules or any shop selling them through social media ads. We don't sell medication, supplements or peptides and never take orders. For an order or refund, contact the seller or your bank or card provider.

Knowledge Base

Resources & Guides

Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.

Showing articles tagged: #ly3437943 Clear filter

Educational Content

View all →
Showing 5 of 5 articles
No articles found matching your search. Try a different term or view all articles.

Retatrutide Injection Sites: Where to Inject and How to Rotate

Retatrutide (LY3437943) is injected subcutaneously once weekly into one of the three sites used in Lilly's injection-site study (NCT05959096): abdomen, thigh, or upper arm. It has no FDA-approved label, so this guide follows that study's sites and general injection technique: each site, how to rotate with every dose, site prep, and which local reactions to watch for.

Best Time to Take Retatrutide: Day, Time, and Meals

A pharmacokinetics-backed guide to retatrutide injection timing: why the ~6-day half-life makes time of day flexible, how to pick a consistent weekly injection day, the morning-versus-evening trade-offs, meal timing on injection day, and bloodwork logistics.

What Is Retatrutide? Complete Guide to the Triple-Agonist Weight Loss Drug

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24.2% weight loss, the highest ever recorded for a GLP-1 class drug. Learn everything about this breakthrough medication.

How to Inject Retatrutide: Step-by-Step Technique Guide

A step-by-step guide to the retatrutide injection technique, from drawing your dose to sharps disposal. Covers vial-and-syringe and pen formats, needle angle, the pinch, and site rotation, based on the published trial literature and standard subcutaneous injection practice.

When Will Retatrutide Be FDA Approved? Timeline, Trials & Projections (2026)

A current read on the retatrutide FDA timeline. The molecule is still investigational, Lilly plans an FDA filing in early 2027, and FDA's usual review times would put a decision in late 2027 or 2028 (our estimate, not Lilly's). Here is what TRIUMPH Phase 3 has reported, what happens next, and how the timeline compares with tirzepatide.